Last reviewed · How we verify
Preservative-free bimatoprost
Preservative-free bimatoprost is a Prostaglandin F analog Small molecule drug developed by Association for Innovation and Biomedical Research on Light and Image. It is currently FDA-approved for Open-angle glaucoma, Ocular hypertension.
Bimatoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.
Bimatoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Preservative-free bimatoprost |
|---|---|
| Sponsor | Association for Innovation and Biomedical Research on Light and Image |
| Drug class | Prostaglandin F analog |
| Target | Prostaglandin F (FP) receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Bimatoprost binds to prostaglandin F (FP) receptors on the ciliary muscle bundle and trabecular meshwork, enhancing drainage of aqueous humor through the uveoscleral (unconventional) pathway. This increased outflow reduces intraocular pressure, making it effective for glaucoma and ocular hypertension. The preservative-free formulation minimizes ocular surface irritation and toxicity associated with benzalkonium chloride and other preservatives.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Iris pigmentation increase
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Periocular skin pigmentation
Key clinical trials
- AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (PHASE1, PHASE2)
- Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension (PHASE3)
- Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
- Comparison of Different Drugs on Ocular Surface Disease in Glaucoma Patients: a Prospective Randomised Study
- Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml (PHASE4)
- Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study (PHASE4)
- Efficacy of Changing to TRAVATAN® From Prior Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Preservative-free bimatoprost CI brief — competitive landscape report
- Preservative-free bimatoprost updates RSS · CI watch RSS
- Association for Innovation and Biomedical Research on Light and Image portfolio CI
Frequently asked questions about Preservative-free bimatoprost
What is Preservative-free bimatoprost?
How does Preservative-free bimatoprost work?
What is Preservative-free bimatoprost used for?
Who makes Preservative-free bimatoprost?
What drug class is Preservative-free bimatoprost in?
What development phase is Preservative-free bimatoprost in?
What are the side effects of Preservative-free bimatoprost?
What does Preservative-free bimatoprost target?
Related
- Drug class: All Prostaglandin F analog drugs
- Target: All drugs targeting Prostaglandin F (FP) receptor
- Manufacturer: Association for Innovation and Biomedical Research on Light and Image — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Open-angle glaucoma
- Indication: Drugs for Ocular hypertension